to Enhance Face of Plastic Surgery FDA Panel Recommends Conditional Approval of Restylane and Hylaform
ARLINGTON HEIGHTS, Ill. – The American Society of Plastic Surgeons (ASPS) welcomes the U.S. Food and Drug Administration (FDA) advisory panel’s recommendation today for conditional approval of Restylane and Hylaform, two new longer lasting, non-surgical wrinkle fighters.
Restylane and Hylaform are hyaluronic acid-based soft tissue fillers that are already used in Canada and Europe to plump wrinkles with immediate results. Hyaluronic acid is a sugar molecule that occurs naturally in the body, so allergic reactions are rare.
47 percent of plastic surgeons responding to a recent ASPS survey believe injectables can enhance the results of facial surgery.
Last year, more than 1.5 million Americans smoothed wrinkles with injectables, according to the ASPS. Almost 5 million Americans had non-surgical cosmetic plastic surgery procedures in 2002. The FDA panel’s recommendation for conditional approval of Restylane and Hylaform will almost certainly mean demand for injectables, an ever-growing segment in plastic surgery, will increase.
“This is the first time in over a decade that patients and physicians have the option of new fillers,” said ASPS President Rod Rohrich , MD. “People want to look as good as they feel using modern techniques and technologies. These wrinkle fillers are safe, do not require a skin test and are two to three times longer lasting.”
43 percent of plastic surgeons responding to a recent ASPS survey say injectables can postpone facial surgery.
As with all plastic surgery procedures, anyone interested in injectable wrinkle fillers should seek a plastic surgeon certified by the American Board of Plastic Surgery (ABPS). As surgeons trained to reconstruct the face at all levels (bone, muscle and skin) plastic surgeons are uniquely qualified to understand the anatomy as it relates to the use of injectables.